Fredun Pharmaceuticals Share Price

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	213.06	160.92	145.29	119.86	167.41
Total Income Growth (%)	32.40	10.76	21.22	-28.41	-
Total Expenses	187.32	136.37	124.85	104.28	152.00
Total Expenses Growth (%)	37.36	9.22	19.73	-31.39	-
EBIT	25.73	24.55	20.44	15.57	15.41
EBIT Growth (%)	4.81	20.14	31.24	1.04	-
Profit after Tax (PAT)	10.78	10.48	9.43	6.77	6.00
PAT Growth (%)	2.88	11.09	39.40	12.70	-
EBIT Margin (%)	12.08	15.26	14.07	12.99	9.21
Net Profit Margin (%)	5.06	6.51	6.49	5.64	3.59
Basic EPS (₹)	19.70	22.19	19.98	14.33	12.71

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	213.05	160.92	145.29	119.86	167.41
Total Income Growth (%)	32.39	10.76	21.22	-28.41	63.01
Total Expenses	187.03	136.37	124.55	104.28	151.22
Total Expenses Growth (%)	37.15	9.49	19.44	-31.04	66.98
EBIT	26.02	24.55	20.74	15.57	16.19
EBIT Growth (%)	5.97	18.40	33.17	-3.81	33.37
Profit after Tax (PAT)	11.07	10.48	9.73	6.77	7.07
PAT Growth (%)	5.60	7.66	43.85	-4.33	32.61
EBIT Margin (%)	12.21	15.26	14.27	12.99	9.67
Net Profit Margin (%)	5.19	6.51	6.70	5.64	4.22
Basic EPS (₹)	20.22	22.19	20.61	14.33	14.98

	FY 2026
Total Revenue	639.12
Total Revenue Growth (%)	40.08
Total Expenses	592.13
Total Expenses Growth (%)	38.10
Profit after Tax (PAT)	32.62
PAT Growth (%)	65.26
Operating Profit Margin (%)	13.57
Net Profit Margin (%)	5.13
Basic EPS (₹)	66.81

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	639.12	456.27	349.07	276.50	226.09
Total Revenue Growth (%)	40.08	30.71	26.25	22.30	67.11
Total Expenses	591.54	428.00	327.62	258.99	217.49
Total Expenses Growth (%)	38.21	30.64	26.50	19.08	66.12
Profit after Tax (PAT)	33.21	20.81	15.62	10.81	6.34
PAT Growth (%)	59.59	33.18	44.57	70.58	214.46
Operating Profit Margin (%)	13.67	11.16	10.08	9.75	5.91
Net Profit Margin (%)	5.22	4.58	4.48	3.93	2.82
Basic EPS (₹)	68.01	44.83	33.66	24.13	11.28

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 40.08% outperformed its 3 year CAGR of 31.85%. (Source: Standalone Financials)
Employee & Interest Expense
Company has spent 6.18% of its operating revenues towards interest expenses and 5.18% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026
Total Assets	642.08
Total Assets Growth (%)	31.73
Total Liabilities	363.97
Total Liabilities Growth (%)	5.19
Total Equity	278.11
Total Equity Growth (%)	96.71
Current Ratio (x)	1.68
Total Debt to Equity (x)	0.80
Contingent Liabilities	-

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	642.14	486.65	307.60	257.28	186.99
Total Assets Growth (%)	31.95	58.21	19.56	37.59	15.70
Total Liabilities	363.43	345.25	186.13	160.90	118.93
Total Liabilities Growth (%)	5.27	85.49	15.68	35.29	0.32
Total Equity	278.71	141.40	121.47	96.38	68.06
Total Equity Growth (%)	97.11	16.41	26.03	41.61	58.02
Current Ratio (x)	1.68	1.31	1.54	2.04	2.07
Total Debt to Equity (x)	0.80	1.18	0.87	0.90	0.78
Contingent Liabilities	-	-	-	-	-

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026
Net Cash flow from Operating Activities	11.90
Net Cash used in Investing Activities	-73.59
Net Cash flow from Financing Activities	121.45
Net Cash Flow	59.76
Closing Cash & Cash Equivalent	64.98
Closing Cash & Cash Equivalent Growth (%)	1,144.10
Total Debt/ CFO (x)	18.69

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	16.44	-28.88	-0.44	-14.41	-2.38
Net Cash used in Investing Activities	-73.58	-5.99	-7.64	-9.40	-4.13
Net Cash flow from Financing Activities	121.82	38.34	5.99	25.18	7.47
Net Cash Flow	64.67	3.47	-2.08	1.36	0.96
Closing Cash & Cash Equivalent	64.95	4.82	1.35	3.44	2.09
Closing Cash & Cash Equivalent Growth (%)	1,248.70	256.69	-60.69	64.72	84.85
Total Debt/ CFO (x)	13.51	-5.76	-240.51	-6.01	-22.17

All figures in Rs Cr, unless mentioned otherwise

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 11.9 cr is 0.36 times compared to the reported net profit of Rs 32.62 cr. (Source: Consolidated Financials)
Increase in Cash from Investing
Company has used Rs 73.58 cr for investing activities which is an YoY increase of 1127.53%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2026
Return on Equity (%)	11.72
Return on Capital Employed (%)	24.99
Return on Assets (%)	5.08
Interest Coverage Ratio (x)	2.41
Asset Turnover Ratio (x)	1.13
Price to Earnings (x)	28.09
Price to Book (x)	3.29
EV/EBITDA (x)	11.34
EBITDA Margin (%)	14.87

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	11.91	14.71	12.86	11.21	9.30
Return on Capital Employed (%)	25.12	31.78	24.93	17.72	11.71
Return on Assets (%)	5.17	4.27	5.07	4.20	3.38
Interest Coverage Ratio (x)	2.41	2.46	2.85	3.19	3.30
Asset Turnover Ratio (x)	1.13	1.14	1.23	1.24	1.29
Price to Earnings (x)	27.62	15.17	21.60	32.68	64.10
Price to Book (x)	3.28	2.23	2.77	3.66	5.96
EV/EBITDA (x)	11.31	8.66	11.34	14.71	29.59
EBITDA Margin (%)	14.91	12.14	11.17	10.77	6.87

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Fredun Pharma	41.60	5.60	11.72	24.99	5.08	31.85	13.57	5.13	66.81	1.68	0.80	18.69
Amrutanjan Health Care	26.64	12.24	16.77	23.87	13.07	9.58	13.83	9.43	14.47	3.46	0.02	0.00
Shukra Pharma	69.68	17.12	24.55	31.67	18.78	0.70	52.67	38.88	0.50	3.63	0.06	1.28
Jagsonpal Pharm	34.18	5.33	15.59	21.02	13.60	7.19	21.10	14.99	6.40	5.06	0.00	0.00
Fermenta Biotech	18.60	3.37	17.86	22.88	11.20	15.11	19.13	13.37	24.70	1.86	0.27	1.17
Add More

Annual Ratios (%)

Choose from Peers

Syncom Form
Bajaj Healthcare
Lincoln Pharma
Wanbury Ltd
Themis Medicare

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Fredun Pharma Stock Performance	-1.08	9.62	22.12	58.21	192.88	256.67	557.20
Amrutanjan Health Care Stock Performance	-0.54	-0.82	-3.62	-0.62	-26.00	-23.89	-25.06
Shukra Pharma Stock Performance	1.06	4.00	13.08	4.25	65.88	0.00	2093.75
Jagsonpal Pharm Stock Performance	-0.93	-2.29	5.05	15.04	-9.14	54.11	227.72
Fermenta Biotech Stock Performance	1.76	25.53	39.58	42.57	18.84	228.18	46.51
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	24,57,053	44.57 %	0.39
Pledge	0	0.00 %	0.00
FII	58,334	1.06 %	0.00
DII	86,864	1.58 %	0.12
Others	29,10,439	52.79 %	-0.51

Category	Jun 2026	Mar 2026	Dec 2025	Sep 2025
Promoters	44.57	44.17	43.06	48.93
Pledge	0.00	0.00	0.00	0.00
FII	1.06	1.06	0.46	0.01
DII	1.58	1.46	2.08	0.02
Mutual Funds	0.00	0.00	0.00	0.00
Others	52.79	53.30	54.40	51.04

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
General Meeting
-
Jun 08, 2026
Final
7%
May 25, 2026
Bonus
Bonus Ratio: 2 share(s) for every 1 shares held
May 25, 2026

Board Meetings

Announced on	Meeting on
May 15, 2026	May 25, 2026
Audited Results, Dividend & Bonus issue
Jan 30, 2026	Feb 09, 2026
Quarterly Results
Oct 28, 2025	Nov 08, 2025
Quarterly Results
Sep 22, 2025	Sep 25, 2025
Preferential Issue of shares & Others
Jul 14, 2025	Jul 30, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 25, 2026 Jun 23, 2026 7%
Jun 02, 2025 Sep 23, 2025 7%
May 08, 2024 Sep 23, 2024 7%
May 25, 2023 Sep 22, 2023 7%
May 16, 2022 Sep 13, 2022 7%
Bonus
Announced on Ex-Date
May 25, 2026 -
Bonus Ratio: 2 share(s) for every 1 shares held
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Jun 08, 2026 Jun 30, 2026
-
Jan 19, 2026 Feb 16, 2026
-
Oct 01, 2025 Oct 22, 2025
-
Sep 15, 2025 Sep 30, 2025
-
Sep 18, 2024 Sep 30, 2024
A.G.M.

Announced on	Ex-Date	Dividend%
May 25, 2026	Jun 23, 2026	7%
Jun 02, 2025	Sep 23, 2025	7%
May 08, 2024	Sep 23, 2024	7%
May 25, 2023	Sep 22, 2023	7%
May 16, 2022	Sep 13, 2022	7%

Announced on	Ex-Date
May 25, 2026	-
Bonus Ratio: 2 share(s) for every 1 shares held

Announced on	Meeting on
Jun 08, 2026	Jun 30, 2026
-
Jan 19, 2026	Feb 16, 2026
-
Oct 01, 2025	Oct 22, 2025
-
Sep 15, 2025	Sep 30, 2025
-
Sep 18, 2024	Sep 30, 2024
A.G.M.

About Fredun Pharma

Fredun Pharmaceuticals Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 1,558.22 Crore) operating in Pharmaceuticals sector.

Fredun Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2026.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 213.06 Crore, up 32.40 % from last quarter Total Income of Rs 160.92 Crore and up 27.27 % from last year same quarter Total Income of Rs 167.41 Crore. Company has reported net profit after tax of Rs 10.78 Crore in latest quarter.

The company’s top management includes Dr.(Mrs.)Daulat N Medhora, Mr.Fredun Medhora, Mr.Anshu Agarwal, Mrs.Daisy D�souza, Ms.Pooja Narendra Sanghavi, Mrs.Sonal Desai, Ms.Vaishnavi Sahu. Company has R H Nisar & Co. as its auditors. As on 30-06-2026, the company has a total of .55 Crore shares outstanding.

Fredun Pharma Share Price Today is Rs. 2826.60. On previous day, the Fredun Pharma Share Price (NSE) closed at Rs. 2753.7, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 30th Jun, 2026, the promoter held 44.17% of the stake in Fredun Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Fredun Pharma stocks was 1.06% as compared to 0.46% in Mar 2026 with increase of 0.6%. The domestic institutional investors (DII) holdings on 30th Jun, 2026 was 1.46% as compared to 2.08% in Mar 2026 with decrease of 0.62%. Out of the total DII holdings in Fredun Pharma shares 0.0% was held by mutual funds. The rest including public held is 53.31%. Fredun Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Fredun Pharma Dividend: Ever since 1987, Fredun Pharma dividends has been paid out around 11 times. As on 15 Jul, 2026, 03:56 PM IST, The overall dividend yield for Fredun Pharma stands at 0.03%. The last dividend paid was on June 23, 2026 (Rs. 0.7). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 67.94.

Fredun Pharma Bonus: The most recent bonus issue had been in year July 16, 2026 around 0 years ago at 1 : 2 ratio. The first bonus issue was announced in May 2026.

Stock Forecast:
After showing 215.7 Cr. of sales and 33.21% of quarterly net profit, there have been multiple ups and downs in the Fredun Pharma stock prices in the past few weeks. For example, Fredun Pharma stock price on 7th of July 2026 was around Rs. 2589.45. Fredun Pharma share price now stands at an average of Rs. 2826.60. Judging by last week's performance, stock is in up trend.

Fredun Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Fredun Pharma share.

Historical Prices and Performance:
Fredun Pharma, incorporated in 1987 is a Small Cap company (with a market cap of Rs. 1593.72) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Fredun Pharma stock was 11.72%, 13.96%, 12.86%, 11.21% and 9.3% respectively.
The Fredun Pharma share gave a 3 year return of 264.79% as compared to Nifty 50 which gave a return of 22.94%.
Fredun Pharma announced 7.0% final dividend on June 23, 2026.

Key Metrics:
PE Ratio of Fredun Pharma is 40.31
Prices/Sales Ratio of Fredun Pharma is 1.44
Price/Book Ratio of Fredun Pharma is 5.43

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at 40.31 and 5.43 respectively.

Leadership of Fredun Pharma :
Vaishnavi Sahu is Co. Secretary & Compl. Officer
Daulat N Medhora is Chairman & Jt. M. D
Fredun Medhora is Managing Director & CFO
Daisy D�souza is Ind. Non-Executive Director
Anshu Agarwal is Ind. Non-Executive Director
Sonal Desai is Ind. Non-Executive Director
Pooja Narendra Sanghavi is Ind. Non-Executive Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

URMI ESTATE,11th Floor, Ganpatrao Kadam Marg,Mumbai, Maharashtra - 400013

Contact

business@fredungroup.com

http://www.fredungroup.com

PE Ratio(x)	41.60
EPS - TTM(₹)	67.94
MCap(₹ Cr.)	1,558.22
MCap Rank	82
PB Ratio(x)	5.73
Div Yield(%)	0.02
Face Value(₹)	10.00
52W High(₹)	2,950.00
52W Low(₹)	866.05
MCap/Sales	1.44
Beta(1 Month)	0.09
BV/Share(₹)	504.49

1 Day	-1.08%
1 Month	22.12%
3 Months	58.21%
1 Year	192.88%
3 Years	256.67%
5 Years	557.2%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Fredun Pharmaceuticals Share Price

Key Metrics

Fredun Pharma share price insights

Fredun Pharma Share Price Returns

Fredun Pharma Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Fredun Pharma Top Searches

Corporate Actions

About Fredun Pharma

Executive Leadership

Auditors

FAQs about Fredun Pharma share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News